- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01327274
Multicenter Trial of Magnetic Mini-Mover for Pectus Excavatum (3MP)
Phase 3 Multicenter Study of Magnetic Mini-Mover for Pectus Excavatum
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pectus excavatum is the most common congenital chest wall abnormality in children. The investigators have developed a novel method of achieving gradual deformation/reformation of chest wall cartilage. A magnetic force field is used to apply controlled, sustained force to promote biologic reformation of structural cartilage. A magnet is implanted on the sternum and secured through a 2-inch subxiphoid incision as a one-hour outpatient procedure. The magnet (and sternum) is pulled outward by another magnet suspended in a novel, low-profile, lightweight device previously molded to the patient's anterior chest wall. The low-profile, non-obtrusive anterior chest wall prosthesis is held in place by the force field between the two magnets.
In the single-center, FDA-funded trial (IDE G050196), the investigators tested proof of concept, safety and probable benefit of this procedure in 10. In this Phase III multicenter trial, the investigators will further test the safety and efficacy of the procedure in 15 otherwise healthy patients with moderate-to-severe PE, ages 8 to 14. The investigators will be using the next generation Magnetic Mini-Mover Magnimplant device (IDE G090006), a design the investigators believe is much improved in terms of safety and ease of implantation/explantation. Implantation of the Magnimplant will be accomplished in an outpatient procedure. The investigators will document the rate of correction by comparing chest X-ray measurement of the Pectus Severity Index prior to implantation, to that measured after the magnet is removed. Treatment will last 18-24 months, depending on correction and when the patient has completed his or her pubertal growth spurt, as documented by hand x-ray. Explant of the device will be accomplished in an outpatient procedure. The investigators will document safety with an EKG prior to implantation, one month post-implantation, and finally after the magnet is removed. The investigators will document efficacy by comparing pre- and post-treatment PSI, as well as by evaluating patient satisfaction with a post-procedure Quality of Life-type survey. Long-term follow-up will occur at 6, 12, 18, and 24 months after explantation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Shriners Hospitals for Children
-
San Francisco, California, United States, 94158
- UCSF-Benioff Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Otherwise healthy male or female with pectus excavatum deformity
- Between 8 and 14 years of age (inclusive)
- Pectus Severity Index > 3.5 (normal 2.56). NOTE: A pectus severity index of 3.5 or greater qualifies as a moderate-to-severe deformity, and justifies operative intervention
- Ability to read, speak and understand English
- Onset of rapid growth of puberty documented by hand/wrist x-ray in early to mid-puberty (defined as bone age in females of 7-13 years, and males of 9-14 years)
Exclusion Criteria:
- Other congenital anomalies (including significant skeletal anomalies such as scoliosis, bony fusion involving the cervical vertebrae) not directly related to pectus excavatum
- Bleeding disorders
- Heart disease (including arrhythmia)
- Persons with active implantable medical devices (AIMD) such as pacemakers
- Persons with a relative(s) or close family friend(s) living within their households and having a pacemaker
- Persons with arteriovenous malformations
- Chest deformity more complicated than pectus excavatum (e.g., Poland syndrome)
- Persons for whom a foreign body implant would pose a risk (e.g., immunodeficiency)
- Persons at increased risk for general anesthesia (e.g., history of malignant hyperthermia)
- Respiratory conditions that have required steroid treatment (e.g., prednisone) in the last 3 years
- Pregnancy
- Inability to understand or follow instructions
- Refusal to wear the external brace
- Refusal to undergo monthly chest x-rays
- Inability or refusal to return to UCSF for biweekly follow-up visits for the first month after surgery, and monthly thereafter until explant.
- Inability to obtain pre-approval (authorization) from the patient's insurance carrier
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment Arm
This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the interventional treatment arm by having outpatient surgery and the Magnetic MIni-Mover Magnimplant procedure is performed during which the magnetic implant is surgically placed.
After 2 years of treatment with the implanted magnet and brace treatment, the Magnetic Mini-Mover Magnimplant will be explanted.
After surgery and recovery, all subjects will be fitted for an orthotic brace, which houses the external magnet and records brace-wear compliance.
They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25).
|
This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery.
The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum.
Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance.
They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25).
Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Adverse Reactions
Time Frame: During treatment, 24 months
|
All adverse reactions were recorded and reported, including complications from implantation of the device, complications from application of the external device over time (e.g., changes in skin; infection; changes in cardiac electrical function).
|
During treatment, 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comfort and Brace Wear During Treatment
Time Frame: During treatment, 24 months
|
Comfort of the external brace directly affects compliance (i.e., bracewear) and compliance were be measured throughout treatment.
In addition, the satisfaction of the patient and family will be measured using a standard Quality of Life (QOL) questionnaire administered 1 month after implanting the device and 1 month after removing the device.
|
During treatment, 24 months
|
|
Chest Wall Correction, by Pectus Severity Index
Time Frame: 24 months
|
Though not powered to determine efficacy, preliminary efficacy data, as measured by pre and post treatment Pectus Severity Index (Haller Index), was also collected.
Pre-treatment Haller Index was assessed based on computed tomography (CT) of the chest.
One month after implant removal, patients underwent repeat chest CT to evaluate chest wall correction.
|
24 months
|
|
Patient Satisfaction During the Treatment
Time Frame: One month and one year after explant.
|
. Patients were asked to fill out questionnaire at 2 intervals: 1 month after explant and 1 year after explant
|
One month and one year after explant.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael R Harrison, MD, University of California, San Francisco
- Principal Investigator: Benjamin Padilla, MD, University of California, San Francisco
- Principal Investigator: Lan Vu, MD, University of California, San Francisco
Publications and helpful links
General Publications
- Harrison MR, Curran PF, Jamshidi R, Christensen D, Bratton BJ, Fechter R, Hirose S. Magnetic mini-mover procedure for pectus excavatum II: initial findings of a Food and Drug Administration-sponsored trial. J Pediatr Surg. 2010 Jan;45(1):185-91; discussion 191-2. doi: 10.1016/j.jpedsurg.2009.10.032.
- Harrison MR, Estefan-Ventura D, Fechter R, Moran AM Jr, Christensen D. Magnetic Mini-Mover Procedure for pectus excavatum: I. Development, design, and simulations for feasibility and safety. J Pediatr Surg. 2007 Jan;42(1):81-5; discussion 85-6. doi: 10.1016/j.jpedsurg.2006.09.042.
- Harrison MR, Gonzales KD, Bratton BJ, Christensen D, Curran PF, Fechter R, Hirose S. Magnetic mini-mover procedure for pectus excavatum III: safety and efficacy in a Food and Drug Administration-sponsored clinical trial. J Pediatr Surg. 2012 Jan;47(1):154-9. doi: 10.1016/j.jpedsurg.2011.10.039.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FD003341-03-06
- FD-R-01FD-03341 (Other Grant/Funding Number: FDA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pectus Excavatum
-
Hacettepe UniversityCompletedFunnel Chest | Pectus Excavatum | Pectus Excavatum Deformity | Chest DeformitiesTurkey
-
Galderma R&DPharma Consulting Group ABCompletedPectus Excavatum DeformityFrance, Sweden
-
Children's Health System, Inc.Walter Lorenz Surgical CorporationUnknownRepair of Pectus ExcavatumUnited States, Canada
-
Erik de LoosCompleted
-
Ankara Etlik City HospitalRecruitingPectus Excavatum DeformityTurkey (Türkiye)
-
Acibadem UniversityUnknownPhysical Disability | Psychosocial Impairment | Pectus DeformityTurkey
-
Gaziosmanpasa Research and Education HospitalCompletedPectus Excavatum | Pectus Carinatum | Pectus Deformity | Pectus AbnormalitiesTurkey (Türkiye)
-
University Hospital, Strasbourg, FranceRecruiting
-
Başakşehir Çam & Sakura City HospitalRecruitingPectus ExcavatumTurkey
-
Zuyderland Medisch CentrumUnknownPectus ExcavatumNetherlands
Clinical Trials on Magnetic Mini-Mover Procedure (Magnimplant)
-
University of California, San FranciscoFDA Office of Orphan Products DevelopmentCompleted
-
Ain Shams UniversityCompleted
-
Hospital Ambroise Paré ParisCompleted
-
The University of Texas Health Science Center,...WithdrawnPersistent Atrial FibrillationUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Treace Medical Concepts, Inc.TerminatedBunion | Hallux ValgusUnited States
-
National Taiwan University HospitalRecruiting
-
Skolkovo Institute of Science and TechnologyMotorica LLCRecruitingPhantom Limb PainRussian Federation
-
St. Paul's Hospital, CanadaStryker NordicNot yet recruitingHallux Valgus and BunionCanada